Increasing cardiac 18F-fluorodeoxyglucose (FDG) uptake on PET-CT as a biomarker for cardiotoxicity of chemo-radiotherapy in cancer: a myth or a reality?
dc.contributor.author | Basu, Sandip | |
dc.contributor.author | Borde, C. | |
dc.contributor.author | Kand, P. | |
dc.date.accessioned | 2015-08-28T09:55:50Z | |
dc.date.available | 2015-08-28T09:55:50Z | |
dc.date.issued | 2014 | |
dc.description.division | RMC | en |
dc.format.extent | 3306 bytes | |
dc.format.mimetype | text/html | |
dc.identifier.source | Radiotherapy and Oncology, 2014. Vol. 112 (3): pp. 451-452 | en |
dc.identifier.uri | http://hdl.handle.net/123456789/11597 | |
dc.language.iso | en | en |
dc.subject | cardiac 18F-fluorodeoxyglucose | en |
dc.subject | FDG | en |
dc.subject | PET-CT | en |
dc.subject | biomarker | en |
dc.subject | cardiotoxicity | en |
dc.subject | chemo-radiotherapy | en |
dc.subject | cancer | en |
dc.title | Increasing cardiac 18F-fluorodeoxyglucose (FDG) uptake on PET-CT as a biomarker for cardiotoxicity of chemo-radiotherapy in cancer: a myth or a reality? | en |
dc.type | Article | en |